New Treatment Could Upend Standard of Care for Advanced Prostate Cancer

Medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.

In a recent interview with Pharmacy Times, medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer, and how this drug could interrupt the typical standard of care. These new findings will be presented at the American Society of Clinical Oncology 2021 annual meeting.

Morris said the typical sequence for a patient with advanced prostate cancer would begin with a testosterone-lowering agent in combination with an androgen receptor pathway inhibitor or chemotherapy, followed by a treatment that they had not previously received. If it were to be approved in the future, Morris said 177Lu-PSMA-617 could represent a new option.